[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355394-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355394-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","factors-associated-and-survival-outcomes-among-japanese-patients-with-solid-cancer-who-developed-deep-vein-thrombosis-dvt","Factors Associated and Survival Outcomes Among Japanese Patients with Solid Cancer Who Developed Deep Vein Thrombosis (DVT)","","Deep vein thrombosis (DVT) is a frequent and high-risk complication in people with cancer. A retrospective single-center cohort reviewed Japanese patients with solid cancers newly diagnosed between 2013 and 2020 who were suspected of DVT and confirmed or ruled out by definitive imaging at Ehime University Hospital. Among 1399 initial patients, 224 with DVT and 560 without DVT were analyzed. Median overall survival was 5.87 years vs 6.81 years (p=0.0014). Anemia and thrombocytopenia increased DVT incidence. Female DVT patients had worse outcomes, and among gynecologic cancers, apixaban was associated with poorer survival vs other DOACs.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/factors-associated-and-survival-outcomes-among-japanese-patients-with-solid-cancer-who-developed-deep-vein-thrombosis-dvt/355394/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/factors-associated-and-survival-outcomes-among-japanese-patients-with-solid-cancer-who-developed-deep-vein-thrombosis-dvt/355394.png","ImageObject",300,407,{"name":42,"@type":43},"\tCallum ","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What study design and data period were used to evaluate DVT in Japanese solid cancer patients?","Question",{"text":63,"@type":64},"The study used a retrospective single-center cohort review of medical records from 2013 to 2020 at Ehime University Hospital.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which factors were identified as strong risk factors for DVT incidence?",{"text":68,"@type":64},"Anemia (Hb \u003C 11 g/dL) and thrombocytopenia (Plt \u003C 15 x 10^4 / μL) were found to be strong risk factors for increased DVT incidence.",{"name":70,"@type":61,"acceptedAnswer":71},"How did survival outcomes differ between patients with and without DVT?",{"text":72,"@type":64},"Median overall survival was shorter in patients with DVT (5.87 years) than in those without DVT (6.81 years), with p=0.0014.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355394,1790180114,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137451211410,"https://ap-avatar.wpscdn.com/avatar/2000bb0a9246f588df?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786362646172706240","International Journal of General Medicine  \nOpen Access Full Text Article ORIGINAL RESEARCH  \nFactors Associated and Survival Outcomes Among Japanese Patients with Solid Cancer Who Developed Deep Vein Thrombosis (DVT)  \nYuya Masuda 1 , Yoshihiro Yakushijin 1–3 , Shintaro Yamanaka 3 , Shinji Hasebe 3 , Tomomi Fujii4 , Jun Yamanouchi 1 , 5 , Katsuto Takenaka 1 , 5  \n1First Department of Internal Medicine, Ehime University Hospital, Toon city, Ehime, Japan; 2Department of Clinical Oncology, Ehime University Graduate School of Medicine, Toon city, Ehime, Japan; 3Cancer Center, Ehime University Hospital, Toon city, Ehime, Japan; 4Palliative Care Center, Ehime University Hospital, Toon city, Ehime, Japan; 5Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Toon city, Ehime, Japan  \nCorrespondence: Yoshihiro Yakushijin, Department of Clinical Oncology, Ehime University Graduate School of Medicine, Toon city, Ehime, 791-0295, Japan, Tel +81 89 960 5969, Fax +81 89 960 5299, [Email yoshiyak@m.ehime-u.ac.jp](Email yoshiyak@m.ehime-u.ac.jp)  \n\n| Objective: Deep vein thrombosis (DVT) is a common and serious complication in patients with cancer. We retrospectively analyzed patients newly diagnosed with solid cancers in a Japanese cohort.\u003Cbr>Patients or Materials: We retrospectively reviewed the medical records (2013–2020) of Japanese patients with solid cancers who were suspected of having DVT and were diagnosed and treated at Ehime University Hospital. Controls were patients with solid cancersin whom DVT was suspected on physical examination and/or laboratory testing but subsequently ruled out by definitive imaging. Candidate risk and prognostic variables were extracted from electronic medical records. This was a single-center cohort study. Results: Among the initial 1399 patients, 224 with DVT and 560 without DVT (as controls) were included in the final analysis after excluding those with incomplete medical records, missing diagnostic tests, or unclear medical histories. The median overall survival (OS) period was 5.87 years for patients with DVT and 6.81 years for patients without DVT (p=0.0014) . Anemia (Hb \u003C11 g/dl) and thrombocytopenia (Plt \u003C15 x 104 / μL) were found to be strong risk factors related to an increased incidence of DVT. Female cancer patients with DVT had a significantly worse outcome than those without DVT (p=0.028) . Analysis of OS in patients with DVT associated with gynecological cancers following treatment with three different direct oral anticoagulants (DOACs; edoxaban, rivaroxaban, and apixaban) indicated that those treated with apixaban had a significantly worse outcome than those treated with the others (p=0.019) in this Japanese cohort.\u003Cbr>Conclusion: Japanese patients with solid cancers, particularly those with gynecologic cancers, tend to have poorer outcomes when DVT co-occurs with anemia and low platelet counts. In addition, the choice of DOAC for DVT treatment may be associated with differences in prognosis. These exploratory findings require more detailed, adjusted analyses and confirmation using other datasets or populations.\u003Cbr>Keywords: cancer patient, deep vein thrombosis, DVT, prognostic factor, direct oral anticoagulant, DOAC |\n| --- |\n| Introduction\u003Cbr>Venous thromboembolism (VTE)– primarily including deep vein thrombosis (DVT), pulmonary embolism (PE), and mesenteric venous thrombosis (MVT) 1 – occurs in over 20% of cancer patients,2 and has been identified as the second most common cause of death among such patients after the malignancy itself. VTE also leads to increased morbidity, including the need for anticoagulation therapy, delays in chemotherapy administration, a higher risk of fatal bleeding and infarction, and ultimately a reduced quality of life (QOL) .3,4 Recently, two major models have been employed for prediction of VTE in daily practice: the Wells score5 and the Khorana score (KRS) .6 The KRS in particular is widely","cbCaiaH79YDfiR7V","https://ap.wps.com/l/cbCaiaH79YDfiR7V","pdf",4095672,15,"English","# Objective\n# Patients or Materials\n# Results\n# Conclusion\n# Introduction\n## VTE and current prediction models","[{\"question\":\"What study design and data period were used to evaluate DVT in Japanese solid cancer patients?\",\"answer\":\"The study used a retrospective single-center cohort review of medical records from 2013 to 2020 at Ehime University Hospital.\"},{\"question\":\"Which factors were identified as strong risk factors for DVT incidence?\",\"answer\":\"Anemia (Hb \\u003c 11 g/dL) and thrombocytopenia (Plt \\u003c 15 x 10^4 / μL) were found to be strong risk factors for increased DVT incidence.\"},{\"question\":\"How did survival outcomes differ between patients with and without DVT?\",\"answer\":\"Median overall survival was shorter in patients with DVT (5.87 years) than in those without DVT (6.81 years), with p=0.0014.\"}]","Factors Associated and Survival Outcomes Among Japanese Patients with Solid Cancer Who Developed Deep Vein Thrombosis (DVT) | PDF",1790118473,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e0e509f7f5f378332f0d3bea9a3abaa.webp",983,1272,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4e7aa8fa76cff76178e866b30ffa9184.webp",982,1270,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f0378c6be76ebce6b9ab6730d894d977.webp",981,1269,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a188aa2e4e5045a7484bbb42aa5eec50.webp",980,1268]